Immunotherapy may help shrink a tumor or slow the growth of cancer cells. People may have it in combination with other treatments for stomach cancer. Immunotherapy is a treatment that helps the immune ...

Gastric (stomach) cancer remains one of the most common and deadly cancers in East Asia, including Korea. Yet despite its high prevalence, it has received far less molecular attention than colorectal ...

Stomach cancer (medically known as gastric cancer) is a major health issue worldwide. In the United States, stomach cancer is the third most common malignancy related to dietary habits. Having an ...

The treatment goals and options for stomach cancer vary depending on how advanced the cancer is and how far it has spread. Surgery is often an effective treatment option for people with early-stage ...

Metastatic stomach cancer is cancer that has spread beyond your stomach to distant tissues. Treatment generally focuses on extending your life and reducing symptoms. Metastatic stomach cancer is also ...

Stomach cancer, also known as gastric cancer, begins in the cells that line the stomach. The vast majority of stomach cancers are the adenocarcinoma type, which affects the glandular mucus-producing ...

Almost all stomach cancers are adenocarcinomas. But some rarer types may be more aggressive, affecting your treatment options and outlook. Stomach cancer (or gastric cancer) happens when cancerous ...

Adenocarcinoma is the most common form of stomach cancer. It can cause digestive issues and abdominal pain. Its causes stem from genetic, dietary, and lifestyle factors, while treatment ranges from ...

A dangerous stomach condition is silently affecting millions of Americans, often developing for years without obvious symptoms until serious complications emerge. Atrophic gastritis represents one of ...

Stomach cancer, also called gastric cancer, develops when cells in the stomach lining begin to grow out of control. People usually don’t experience any symptoms in the early stages, which makes early ...

The days of broad approvals for PD-1 inhibitors in stomach and esophageal cancers appear to be numbered. A group of external advisers to the FDA voted 10-2 that the use of PD-1 inhibitors in ...